1. Inicio
  2. Publicaciones
  3. Psoriasis induced by antiTNF therapy in inflammatory bowel disease: Therapeutic management and evolution of both diseases in a nationwide cohort study

Psoriasis induced by antiTNF therapy in inflammatory bowel disease: Therapeutic management and evolution of both diseases in a nationwide cohort study

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Segura, PS
  • Gomollón, F
  • Casas, D
  • Vela, M
  • Fernández-Clotet, A
  • Muñoz, R
  • de la Filia, IG
  • Prada, MG
  • Rosique, JAF
  • García, MJ
  • de Francisco, R
  • Arias, L
  • Barrio, J
  • Guerra, I
  • Ponferrada, A
  • Gisbert, JP
  • Carrillo-Palau, M
  • Calvet, X
  • Márquez-Mosquera, L
  • Gros, B
  • Cañete, F
  • Monfort, D
  • Domínguez, REM
  • Roncero, O
  • Laredo, V
  • Montoro, M
  • Muñoz, C
  • López-Cauce, B
  • Lorente, R
  • Coronel, AF
  • Vega, P
  • Martín, D
  • Peña, E
  • Varela, P
  • Olivares, S
  • Pajares, R
  • Lucendo, AJ
  • Sesé, E
  • Mateu, BB
  • Domènech, E
  • García-López, S
  • ENEIDA Project GETECCU

Grupos

Abstract

Background: some patients with inflammatory bowel disease (IBD) treated with antiTNF develop drug-induced psoriasis (antiTNF-IP). Several therapeutic strategies are possible. Aims: to assess the management of antiTNF-IP in IBD, and its impact in both diseases. Methods: patients with antiTNF-IP from ENEIDA registry were included. Therapeutic strategy was classified as continuing the same antiTNF, stopping antiTNF, switch to another antiTNF or swap to a non-antiTNF biologic. IP severity and IBD activity were assessed at baseline and 16, 32 and 54 weeks. Results: 234 patients were included. At baseline, antiTNF-IP was moderate-severe in 60 % of them, and IBD was in remission in 80 %. Therapeutic strategy was associated to antiTNF-IP severity (p < 0.001). AntiTNF-IP improved at week 54 with all strategies, but continuing with the same antiTNF showed the worst results (p = 0.042). Among patients with IBD in remission, relapse was higher in those who stopped antiTNF (p = 0.025). In multivariate analysis, stopping antiTNF, trunk and palms and soles location were associated with antiTNF-IP remission; female sex and previous surgery in Crohns disease with IBD relapse. Conclusion: skin lesions severity and IBD activity seem to determine antiTNF-IP management. Continuing antiTNF in mild antiTNF-IP, and swap to ustekinumab or switch to another antiTNF in moderate-severe cases, are suitable strategies. (c) 2024 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Datos de la publicación

ISSN/ISSNe:
1590-8658, 1878-3562

DIGESTIVE AND LIVER DISEASE  ELSEVIER SCIENCE INC

Tipo:
Article
Páginas:
2060-2068
PubMed:
38876834
Factor de Impacto:
0,979 SCImago ℠
Cuartil:
Q2 SCImago ℠

Citas Recibidas en Web of Science: 2

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Inflammatory bowel disease; Psoriasis induced by antiTNF; Anti-tumour necrosis factor alpha

Campos de Estudio

Cita

Compartir